Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun 20:5:50.
doi: 10.1186/s40425-017-0253-2. eCollection 2017.

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016

Prasad S Adusumilli  1 , Edward Cha  2 , Mark Cornfeld  3 , Thomas Davis  4 , Adi Diab  5 , Thomas W Dubensky Jr  6 , Elizabeth Evans  7 , Jane L Grogan  8 , Bryan A Irving  9 , Rom S Leidner  10 , Shane A Olwill  11 , Patrick Soon-Shiong  12 , Frederic Triebel  13 , David Tuck  14 , Adrian Bot  15 , Roger D Dansey  16 , Charles G Drake  17 , Gordon J Freeman  18 , Ramy Ibrahim  19 , Salil Patel  20 , Daniel S Chen  21
Affiliations
Review

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016

Prasad S Adusumilli et al. J Immunother Cancer. .

Abstract

This report is a summary of 'New Cancer Immunotherapy Agents in Development' program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November 9, 2016 in National Harbor, Maryland. Presenters gave brief overviews of emerging clinical and pre-clinical immune-based agents and combinations, before participating in an extended panel discussion with multidisciplinary leaders, including members of the FDA, leading academic institutions and industrial drug developers, to consider topics relevant to the future of cancer immunotherapy.

Keywords: Cancer; Checkpoint inhibitors; Combination therapy; Immunotherapy; PD-1.

PubMed Disclaimer

References

    1. Evans EE, Jonason AS, Jr, Bussler H, Torno S, Veeraraghavan J, Reilly C, et al. Antibody blockade of semaphorin 4D promotes immune infiltration into tumor and enhances response to other immunomodulatory therapies. Cancer Immunol Res. 2015;3(6):689–701. doi: 10.1158/2326-6066.CIR-14-0171. - DOI - PubMed
    1. Patnaik A, Weiss GJ, Leonard JE, Rasco DW, Sachdev JC, Fisher TL, et al. Safety, pharmacokinetics, and Pharmacodynamics of a humanized anti-semaphorin 4D antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res. 2016;22(4):827–36. doi: 10.1158/1078-0432.CCR-15-0431. - DOI - PubMed
    1. Lundqvist A, van Hoef V, Zhang X, Wennerberg E, Lorent J, Witt K, et al. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. J ImmunoTherapy Cancer. 2016;4(1):82. doi: 10.1186/s40425-016-0172-7. - DOI
    1. Ebert PJ, Cheung J, Yang Y, McNamara E, Hong R, Moskalenko M, et al. MAP Kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity. 2016;44(3):609–21. doi: 10.1016/j.immuni.2016.01.024. - DOI - PubMed
    1. Hwu P, Hamid O, Gonzalez R, Infante JR, Patel MR, Hodi FS, et al. Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma. Ann Oncol. 2016;27(suppl_6):1109PD.

MeSH terms

Substances